The short version
FDA approved Forzinity in September 2025 through accelerated approval for improving muscle strength in people with Barth syndrome weighing at least 30 kg. Approval does not apply to general fitness or longevity use.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- SS-31
- Entry name · The name used for this encyclopedia topic.
- Elamipretide
- Scientific name · The medicine ingredient also studied under SS-31; this does not verify a product sold under that label.
- Forzinity
- Prescription product name · FDA-approved elamipretide product for a specific Barth syndrome indication, not approval of every SS-31 preparation.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What should be clarified before interpreting claims?
The 12-person randomized study did not beat placebo on walking distance or fatigue; strength increases appeared during the open-label extension. Confirmatory evidence remains important.
Identity and evidence scope · FDA · Forzinity trial snapshot ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The 12-person randomized study did not beat placebo on walking distance or fatigue; strength increases appeared during the open-label extension. Confirmatory evidence remains important.
Research terms in everyday language ↗
This is a bounded context overview, not a completed clinical literature appraisal. The linked source has the scope stated here; related-compound findings are not evidence for this preparation.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Elamipretide, also known as SS-31, has a narrow prescription-product use in Barth syndrome.
- Name variations
- Names you may see and important distinctions
- Source type
- FDA trial and approval summary
- Reference jurisdiction
- Research context; approval is product- and country-specific
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗